Literature DB >> 28838463

Beware Cold Agglutinins in Organ Donors! Ex Vivo Lung Perfusion From an Uncontrolled Donation After Circulatory-Determination-of-Death Donor With a Cold Agglutinin: A Case Report.

A Venkataraman1, J W Blackwell1, W K Funkhouser2, K R Birchard3, S E Beamer1, W T Simmons1, S H Randell4, T M Egan5.   

Abstract

BACKGROUND: We began to recover lungs from uncontrolled donation after circulatory determination of death to assess for transplant suitability by means of ex vivo lung perfusion (EVLP) and computerized tomographic (CT) scan. Our first case had a cold agglutinin with an interesting outcome. CASE REPORT: A 60-year-old man collapsed at home and was pronounced dead by Emergency Medical Services personnel. Next-of-kin consented to lung retrieval, and the decedent was ventilated and transported. Lungs were flushed with cold Perfadex, removed, and stored cold. The lungs did not flush well. Medical history revealed a recent hemolytic anemia and a known cold agglutinin. Warm nonventilated ischemia time was 51 minutes. O2-ventilated ischemia time was 141 minutes. Total cold ischemia time was 6.5 hours. At cannulation for EVLP, established clots were retrieved from both pulmonary arteries. At initiation of EVLP with Steen solution, tiny red aggregates were observed initially. With warming, the aggregates disappeared and the perfusate became red. After 1 hour, EVLP was stopped because of florid pulmonary edema. The lungs were cooled to 20°C; tiny red aggregates formed again in the perfusate. Ex vivo CT scan showed areas of pulmonary edema and a pyramidal right middle lobe opacity. Dissection showed multiple pulmonary emboli-the likely cause of death. However, histology showed agglutinated red blood cells in the microvasculature in pre- and post-EVLP biopsies, which may have contributed to inadequate parenchymal preservation.
CONCLUSIONS: Organ donors with cold agglutinins may not be suitable owing to the impact of hypothermic preservation.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28838463      PMCID: PMC6034983          DOI: 10.1016/j.transproceed.2017.04.004

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  14 in total

1.  Clinical lung transplantation from uncontrolled non-heart-beating donors revisited.

Authors:  David Gomez-de-Antonio; Jose Luis Campo-Cañaveral; Silvana Crowley; Daniel Valdivia; Mar Cordoba; Javier Moradiellos; Jose Manual Naranjo; Piedad Ussetti; Andrés Varela
Journal:  J Heart Lung Transplant       Date:  2012-02-03       Impact factor: 10.247

2.  Normothermic ex vivo lung perfusion in clinical lung transplantation.

Authors:  Marcelo Cypel; Jonathan C Yeung; Mingyao Liu; Masaki Anraku; Fengshi Chen; Wojtek Karolak; Masaaki Sato; Jane Laratta; Sassan Azad; Mindy Madonik; Chung-Wai Chow; Cecilia Chaparro; Michael Hutcheon; Lianne G Singer; Arthur S Slutsky; Kazuhiro Yasufuku; Marc de Perrot; Andrew F Pierre; Thomas K Waddell; Shaf Keshavjee
Journal:  N Engl J Med       Date:  2011-04-14       Impact factor: 91.245

Review 3.  A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.

Authors:  David Weill; Christian Benden; Paul A Corris; John H Dark; R Duane Davis; Shaf Keshavjee; David J Lederer; Michael J Mulligan; G Alexander Patterson; Lianne G Singer; Greg I Snell; Geert M Verleden; Martin R Zamora; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2014-06-26       Impact factor: 10.247

4.  Ex vivo evaluation of human lungs for transplant suitability.

Authors:  Thomas M Egan; John A Haithcock; William A Nicotra; Giovanna Koukoulis; Hidetoshi Inokawa; Mayura Sevala; Paul L Molina; William K Funkhouser; Burton J Mattice
Journal:  Ann Thorac Surg       Date:  2006-04       Impact factor: 4.330

Review 5.  Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.

Authors:  Sigbjørn Berentsen; Geir E Tjønnfjord
Journal:  Blood Rev       Date:  2012-02-12       Impact factor: 8.250

6.  A strategy to increase the donor pool: use of cadaver lungs for transplantation.

Authors:  T M Egan; C J Lambert; R Reddick; K S Ulicny; B A Keagy; B R Wilcox
Journal:  Ann Thorac Surg       Date:  1991-11       Impact factor: 4.330

7.  Cold agglutinins in patients undergoing cardiac surgery requiring cardiopulmonary bypass.

Authors:  David W Barbara; William J Mauermann; James R Neal; Martin D Abel; Hartzell V Schaff; Jeffrey L Winters
Journal:  J Thorac Cardiovasc Surg       Date:  2013-04-13       Impact factor: 5.209

8.  Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo.

Authors:  Richard Ingemansson; Atli Eyjolfsson; Lena Mared; Leif Pierre; Lars Algotsson; Björn Ekmehag; Ronny Gustafsson; Per Johnsson; Bansi Koul; Sandra Lindstedt; Carsten Lührs; Trygve Sjöberg; Stig Steen
Journal:  Ann Thorac Surg       Date:  2009-01       Impact factor: 4.330

9.  Lung Quality and Utilization in Controlled Donation After Circulatory Determination of Death Within the United States.

Authors:  J J Mooney; H Hedlin; P K Mohabir; R Vazquez; J Nguyen; R Ha; P Chiu; K Patel; M R Zamora; D Weill; M R Nicolls; G S Dhillon
Journal:  Am J Transplant       Date:  2016-02-04       Impact factor: 8.086

10.  Successful Transplantation of Lungs From an Uncontrolled Donor After Circulatory Death Preserved In Situ by Alveolar Recruitment Maneuvers and Assessed by Ex Vivo Lung Perfusion.

Authors:  F Valenza; G Citerio; A Palleschi; A Vargiolu; B Safaee Fakhr; A Confalonieri; M Nosotti; S Gatti; S Ravasi; S Vesconi; A Pesenti; F Blasi; L Santambrogio; L Gattinoni
Journal:  Am J Transplant       Date:  2016-01-30       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.